EOM Pharmaceutical Holdings, which is developing in-licensed therapies for inflammatory and ocular diseases, withdrew its plans for an initial public offering on Wednesday. It originally filed in June 2022 with a proposed deal size of $25 million. The company is currently listed on the OTC Pink under the ticker "IMUC".
The Montvale, NJ-based company was founded in 2020 and had planned to list on the Nasdaq under the symbol EOM. EF Hutton was set to be the sole bookrunner on the deal.
